+1 (619) 956-9114 info@myicfos.com
Follow us

iCFO Capital Global partnered with Adlore to raise $3.2M in a Series A.

February 13, 2024 by
iCFO Capital Global partnered with Adlore to raise $3.2M in a Series A.
Alejandra Rosas

SAN DIEGO, CALIFORNIA - iCFO Capital Global, Inc., recently partnered with Adlore to raise $3.2M in a Series A from iCFO Capital Global investor network nationwide.

Adlore, Inc® was founded to develop SenLoreTM, a smart boot, a game-changer in the industry using remote patient monitoring (RPM) to treat and monitor diabetic foot ulcers (DFUs) at home in an extended nursing facility. SenLore will be a therapeutic boot device to accelerate wound healing by combining controlled heat and electrical stimulation (ES) to increase blood flow to the wound site and feedback sensors to monitor performance for remote patient monitoring. The boot device addresses a significant medical problem, by improving treatment efficacy and reducing the cost of care.

The services use RPM to monitor wounds with information with biomarkers about the wounds health going to the clinicians and electronic medical records.

The benefits are also the healthcare providers who administer care and treatment for DFUs, especially in rural areas of healthcare disparity.  

Healthcare providers include primary care physicians, internal medicine physicians, podiatrists, vascular and orthopedic surgeons, and other healthcare professionals that comprise a wound care team (RNs and physical therapists).  

The idea of (RPM) with The Senlore TM device for people at home and treatment is very exciting and a game-changer for all clinicians treating these challenging wounds. It is also exciting that there are new reimbursement codes for RPM for each patient.

5 Key Company Highlights

  1. Studies conducted at a leading University achieved diabetic foot ulcer healing rates of up to 70% compared to the current standard of care of ~24% when using the combination of electrical stimulation and safe heat.  This data was a driving force to start Adlore. 
  2. Adlore has developed a prototype incorporating electrical stimulation and safe heat and conducted a pilot study.  The data showed a significant increase in blood perfusion,  contributing to improved healing rates and reduced pain.
  3. The USPTO has issued two U.S. patents, and Adlore has filed Patent Cooperation Treaty (PCT) applications.  The PCT is going through a regular review process.
  4. Adlore is working with a leading engineering firm to design and develop the SenLore boot and collaborating with the Western Michigan University Engineering Department to test non-adhesive electrodes and sensors.
  5. The activities necessary to complete the development of the SenLore device, conduct a clinical study, and obtain regulatory approval are well established and risks are minimal.  The estimated time is 18-24 months.

Eli Thomssen, MBA - President & CEO

  • Formerly VP, Business Development at Pharmacia & Upjohn Animal Health
  • Founding partner of the Apjohn Group
  • Founding member of 5 companies with 4 exits
  • Eli spent most of his career working in the animal health division of The Upjohn Company which merged with Pharmacia to become Pharmacia & Upjohn. 
  • Eli has a Bachelor of Science degree from the University of Nebraska and an MBA from Western Michigan University.

For more information about the company, visit: https://adloreinc.com/

iCFO Capital Global, Inc. provides a platform for Entrepreneurs to connect with our Private Investors that makes direct debt and equity investment for early-stage and expand growth businesses. To learn more about how your business can secure the funding it needs, visit: https://www.icfocapital.com/

Schedchule a meeting with our Managing Director, Khris Thetsy at the following link: https://calendly.com/icfo-khristhetsy